/IBO

IBO Stock - Impact BioMedical Inc.

Q: What is the analyst price target for IBO?

Analyst price target information is not currently available for IBO.

Q: What is IBO's market cap?

Market capitalization information is not currently available for IBO.

Healthcare|Biotechnology|AMEX

$0.65+46.26%

+$0.21 (+46.26%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.71

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IBO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta6.69

52W High$6.17

52W Low$0.36

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024
Revenue	$2.33M
Gross Profit	$2.33M
Gross Margin	100.0%
Operating Income	$551,664
Net Income	$-2,051,587
Net Margin	-88.0%
EPS	$-0.01

Company Overview

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.

Visit Website

Earnings History & Surprises

IBO

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.12

Q4 2025

EPS Surprise History

Q4 24

No data

Q1 25

No data

Q2 25

No data

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 7, 2025	—	$-0.12	—	—
Q3 2025	Aug 14, 2025	—	$-1.18	—	—
Q2 2025	May 14, 2025	—	$-0.11	—	—
Q1 2025	Mar 28, 2025	—	$-0.42	—	—
Q4 2024	Nov 12, 2024	—	$-0.02	—	—